𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 1 trial of active specific intralymphatic immunotherapy in patients with advanced cancer

✍ Scribed by Guy Juillard; Pamela Boyer; Charles Yamashiro

Publisher
Elsevier Science
Year
1977
Tongue
English
Weight
99 KB
Volume
2
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I immunotherapy with a modified va
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
✍ Professor Christoph Rochlitz; Robert Figlin; Patrick Squiban; Marc Salzberg; Mik πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 145 KB

## Abstract ## Background The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many types of tissues. MUC1 is expressed, but heavily underglycosylated, in different human tumors. TG4010 is a viral suspension of a recombinant va

Phase 1 trial of everolimus and gefitini
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 3 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos